



## ASX ANNOUNCEMENT

### **Change of Share Register Notification**

**Sydney, 28 May 2021.** Actinogen Medical (ASX: ACW) ('ACW' or 'the Company') advises that it will change its provider for shareholder registry services from Link Market Services Limited to Automic Pty Ltd ("Automic") effective from start of business on Monday 31 May 2021.

The new Share Registry details are as follows:

**Street Address:**

Automic Pty Ltd  
Level 5, 126 Phillip Street  
Sydney NSW 2000

**Postal Address:**

GPO Box 5193  
Sydney NSW 2001

We encourage shareholders that are not already a user of Automic's investor portal to sign up and register their details via the website (<https://investor.automic.com.au>).

For guidance on how to register, please refer to the Automic website <https://investor.automic.com.au/#/support/1/sub?faqId=13>.

The Automic portal will allow shareholders to manage their holdings easily and efficiently via Automic's secure and highly accessible online investor portal. The portal provides, among other things, an online interface to update and manage shareholder details, view balances and transaction history.

Shareholders with any queries in relation to their account with Actinogen Medical Limited holding are advised to contact Automic at [hello@automicgroup.com.au](mailto:hello@automicgroup.com.au) or on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia).

**ENDS**

**Actinogen Medical**

Dr. Steven Gourlay  
CEO & Managing Director  
P: +61 2 8964 7401  
E: [steven.gourlay@actinogen.com.au](mailto:steven.gourlay@actinogen.com.au)

**Investor Enquiries**

Miranda Newnham  
Vesparum Capital  
P: +61 3 8582 4800  
E: [actinogen@vesparum.com](mailto:actinogen@vesparum.com)

***Announcement authorised by the Board of Directors of Actinogen Medical***

**About Actinogen Medical**

Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing novel therapies for neurological diseases associated with dysregulated brain cortisol. The company is currently developing its lead compound, Xanamem™, as a promising new therapy for Alzheimer's Disease, Fragile X syndrome, and other potential neurological diseases. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

### **About Xanamem™**

Xanamem's novel mechanism of action works by blocking the production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to detrimental changes in the brain, affecting memory, cognitive function and behaviour and neuropsychological symptoms.

The Company has studied 11β-HSD1 inhibition by Xanamem in more than 200 volunteers and patients, finding a statistically significant improvement in cognition over placebo in healthy, older volunteers. A series of Phase II studies in multiple indications will be conducted to further confirm and characterise Xanamem's efficacy and safety.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem™ is a trademark of Actinogen Medical.

### **Disclaimer**

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies, and regulatory and clinical development risks and uncertainties) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**